Clinical Trial Update: Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 safety and efficacy trial of Serostim for HIV-associated adipose redistribution syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hiv-associated Adipose Redistribution Syndrome

Drugs mentioned

• SEROSTIM (somatropin)

Snippet

Sponsor: EMD Serono | Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections | Phase 2, Phase 3 | Status: COMPLETED